{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-23-000039","form_type":"8-K","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.639430+00:00","generated_at":"2026-06-16T01:06:05.585020+00:00","sec_items":["2.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Avanos Medical reports Q1 results and holds annual meeting; all proposals approved","bullets":["Q1 2023 earnings released May 3, 2023; no financial figures provided in the filing.","Annual meeting held Apr 27, 2023; 94.23% of shares represented (43,916,111 shares).","All six director nominees elected; Dr. Julie Shimer received lowest support (35.5M for, 6.2M withheld).","Delaware auditor ratified (43.5M for, 0.27M against); advisory say-on-pay approved (38.96M for, 2.59M against).","LTIP amended to increase authorized shares by 1.25M (39.96M for, 1.59M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-23-000039","json":"https://secwatch.observer/filing/0001606498-23-000039.json","markdown":"https://secwatch.observer/filing/0001606498-23-000039.md","text":"https://secwatch.observer/filing/0001606498-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000039/0001606498-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000039/avns-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:06:05.585020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1df6cdbf8f632105189e16c3457c198e8eb7389e","claim":"AVANOS MEDICAL, INC. reported financial results for the three months ended March 31, 2023.","evidence_excerpt":"Avanos Medical, Inc. (the “Company”) announced its results of operations for the three months ended March 31, 2023 in a press release dated May 3, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000039/0001606498-23-000039-index.htm","confidence":0.81,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"73e29670ed47bde860b7d94776c1050ec78e69ed","claim":"AVANOS MEDICAL, INC. shareholders approved Approve an amendment to the Company’s 2021 Long Term Incentive Plan to increase the number of shares reserved for issuance at the 2023-04-27 meeting.","evidence_excerpt":"The votes cast on Proposal No. 4 were as follows: For Against Abstain Broker non-votes Amendment of the 2021 Long Term Incentive Plan 39,961,025 1,585,386 112,920 2,256,780","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000039/0001606498-23-000039-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"82d0c8699e3c8cf7fa91f23378fe803183824978","claim":"AVANOS MEDICAL, INC. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2023 at the 2023-04-27 meeting.","evidence_excerpt":"The votes cast on Proposal No. 2 were as follows: For Against Abstain Appointment of Deloitte & Touche LLP 43,502,269 268,752 145,090","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000039/0001606498-23-000039-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"a505b579882a03848d671ebd3e95bb5739af9341","claim":"AVANOS MEDICAL, INC. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-04-27 meeting.","evidence_excerpt":"The votes cast on Proposal No. 3 were as follows: For Against Abstain Broker non-votes Approval of NEO compensation 38,956,746 2,593,580 109,005 2,256,780","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000039/0001606498-23-000039-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"e5513043f90f5c52e50951572c8b9b9b8f3ee69d","claim":"AVANOS MEDICAL, INC. shareholders approved Election of directors at the 2023-04-27 meeting.","evidence_excerpt":"The votes cast on Proposal No. 1 were as follows: Director For Withhold Broker non-votes Gary D. Blackford 40,939,693 719,638 2,256,780 John P. Byrnes 41,020,988 638,343 2,256,780 Dr. Lisa Egbuonu-Davis 41,187,183 472,148 2,256,780 Patrick J. O’Leary 41,327,319 332,012 2,256,780 Dr. Julie Shimer 35,455,820 6,203,511 2,256,780 Joseph F. Woody 41,422,567 236,764 2,256,780","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000039/0001606498-23-000039-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}